君实生物:特瑞普利单抗新适应症补充申请获受理 拓展至II-III期可切除非小细胞肺癌

财中社
Jul 21

7月21日,君实生物(688180/01877)发布公告,公司收到国家药品监督管理局核准签发的《受理通知书》,特瑞普利单抗联合含铂化疗围手术期治疗可切除II-III期非小细胞肺癌的补充申请获得受理。  本次申请的适应症由可切除IIIA-IIIB期非小细胞肺癌扩展为可切除II-III期非小细胞肺癌。由于药品研发周期长,审批环节多,本次补充申请能否获得批准存在不确定性。  2026年一季度,君实生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10